Title:
MAMMALIAN GENES INVOLED IN RAPAMYCIN RESISTANCE AND TUMORGENESIS: ANNEXIN XIII GENES
Document Type and Number:
WIPO Patent Application WO2003094841
Kind Code:
A3
Abstract:
The present invention provides methods and compositions for regulating rapamycin resistance and/or tumorgenesis by modulating the expression and/or the activity of annexin XIII gene. The invention also provides methods and compositions for treatment of diseases, e.g., cancers, by modulating the expression and/or activity of annexin XIII gene. The invention also provides methods and compositions for diagnosing and screening annexin XIII mediated rapamycin resistance and/or tumorgenesis in patients. The invention further provides host cells whose annexin XIII gene can be reversibly switched on or off, and to methods of using annexin XIII gene in evaluation and screening for drugs which regulate rapamycin resistance and/or tumorgenesis. The invention also provides methods for generating genetically modified cells having altered sensitivity to rapamycin by knocking out a gene which mediates rapamycin resistance.
Inventors:
LI LIMIN (US)
Application Number:
PCT/US2003/013908
Publication Date:
July 01, 2004
Filing Date:
May 06, 2003
Export Citation:
Assignee:
FUNCTIONAL GENETICS INC (US)
LI LIMIN (US)
LI LIMIN (US)
International Classes:
C12Q1/68; (IPC1-7): C12Q1/68; A61K48/00
Other References:
HUANG ET AL.: "Mechanisms of resistance to rapamycins", DRUG RESIST UPDATES, vol. 4, 2001, pages 378 - 391, XP001094520
HUANG ET AL.: "Resistance to rapamycin: a novel anticancer drug", CANCER METASTASIS REV., vol. 20, 2001, pages 69 - 78, XP002976743
HUANG ET AL.: "Resistance to rapamycin: a novel anticancer drug", CANCER METASTASIS REV., vol. 20, 2001, pages 69 - 78, XP002976743
Download PDF:
Previous Patent: INDUCTION OF ANTIGEN SPECIFIC IMMUNOLOGIC TOLERANCE
Next Patent: CONJUGATES COMPRISING CENTRAL NERVOUS SYSTEM ACTIVE DRUG
Next Patent: CONJUGATES COMPRISING CENTRAL NERVOUS SYSTEM ACTIVE DRUG